Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2013.05.008PMID 23806981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

  2012cited by this paper
• Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.

  2012cited by this paper
• Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines

  2012cited by this paper
• Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

  2011cited by this paper
• A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status.

  2011cited by this paper
• Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).

  2011cited by this paper
• EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

  2011cited by this paper
• EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients

  2011cited by this paper
• Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

  2011cited by this paper
• Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

  2011cited by this paper
• Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.

  2011cited by this paper
• Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

  2011cited by this paper
• Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

  2011cited by this paper
• Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

  2011cited by this paper
• Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group.

  2011cited by this paper
• KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

  2011cited by this paper
• Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

  2011cited by this paper
• The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

  2011cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan

  2010cited by this paper
• Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer.

  2010cited by this paper
• Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.

  2010cited by this paper
• Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

  2010cited by this paper
• Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

  2010cited by this paper
• Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

  2010cited by this paper
• Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

  2010cited by this paper
• Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan

  2010cited by this paper
• Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

  2009cited by this paper
• PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

  2009cited by this paper
• PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

  2009cited by this paper
• PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

  2009cited by this paper
• Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

  2009cited by this paper
• PTEN status in advanced colorectal cancer treated with cetuximab

  2009cited by this paper
• HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

  2009cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

  2009cited by this paper
• Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

  2009cited by this paper
• Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

  2008cited by this paper
• Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

  2008cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

  2007cited by this paper
• EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer

  2007cited by this paper
• Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

  2006cited by this paper
• Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab

  2006cited by this paper
• let-7 microRNA functions as a potential growth suppressor in human colon cancer cells.

  2006cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.

  2003cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper

• Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

  2021cites this paper
• Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling

  2020cites this paper
• Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.

  2020cites this paper
• Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

  2020cites this paper
• MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling

  2020cites this paper
• Genética del carcinoma colorrectal con agregación familiar, en una muestra de la Región Andina colombiana

  2019cites this paper
• Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab

  2019cites this paper
• Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

  2019cites this paper
• Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer

  2019cites this paper
• Photothermal therapy with AuNRs and EGFRmAb-AuNRs inhibits subcutaneous transplantable hypopharyngeal tumors in nude mice.

  2018cites this paper
• BRAF-mutant colorectal cancer, a different breed evolving

  2018cites this paper
• terminal-deoxynucleotidyl transferase dUTP nick end labeling assay were adopted to detect apoptosis of cells in the trans- planted tumors. Reverse transcription-quantitative polymerase chain reaction and western blotting were used to determine the mRNA and protein expression levels of target genes,

  2018cites this paper
• MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer.

  2016cites this paper
• High-Temperature Hyperthermic Intraperitoneal Chemotherapy (H-HIPEC) with Cytoreductive Surgery for Patients with Peritoneal Metastases of Colorectal Cancer and Appendiceal Pseudomyxoma

  2016cites this paper
• Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.

  2016cites this paper
• Expression of hepatocyte growth factor and c-Met is characteristic of α-fetoprotein-producing colorectal adenocarcinoma: A report of three cases.

  2016cites this paper
• MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer

  2015cites this paper
• Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

  2015cites this paper
• Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

  2015cites this paper
• c-Met as a Target for Personalized Therapy

  2015cites this paper
• Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab

  2015cites this paper
• Supplementary Issue: Pharmacodynamic Biomarkers of Response and Resistance

  2015cites this paper
• Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer

  2015cites this paper
• The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors

  2015cites this paper
• Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.

  2014cites this paper
• The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

  2014cites this paper
• [Biotherapies in metastatic colorectal cancers in 2014].

  2014cites this paper
• Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers.

  2014cites this paper
• Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.

  2014cites this paper